Targeting of drug nanocarriers (NCs) to intercellular adhesion molecule-1 (ICAM-1), an endothelialsurface protein overexpressed in many pathologies, has shown promise for therapeutic delivery into and across this lining. However, due to the role of ICAM-1 in inflammation, the effects of targeting this receptor need investigation. Since ICAM-1 binding by natural ligands (leukocyte integrins) results in release of the "soluble ICAM-1" ectodomain (sICAM-1), an inflammatory regulator, we investigated the influence of targeting ICAM-1 with NCs on this process. For this, sICAM-1 was measured by ELISA from cell-medium supernatants, after incubation of endothelial cell (EC) monolayers in the absence versus presence of anti-ICAM NCs. In the absence of NCs, ECs released sICAM-1 when treated with a pro-inflammatory cytokine. This was reduced by inhibiting matrix metalloproteinases MMP-9 or MMP-2, yet inhibiting both did not render additive effects. Release of sICAM-1 mainly occurred at the basolateral versus apical side, and both MMP-9 and MMP-2 influenced apical release, while basolateral release depended on MMP-9. Interestingly, anti-ICAM NCs reduced sICAM-1 to a greater extent than MMP inhibition, both at the apical and basolateral sides. This effect was enhanced with time, although NCs had been removed after binding to cells, ruling out a "trapping" effect of NCs. Instead, inhibiting anti-ICAM NC endocytosis counteracted their inhibition on sICAM-1 release. Hence, anti-ICAM NCs inhibited sICAM-1 release by mobilizing ICAM-1 from the cell-surface into intracellular vesicles. Since elevated levels of sICAM-1 associate with numerous diseases, this effect represents a secondary benefit of using ICAM-1-targeted NCs for drug delivery.
Interestingly, engagement of ICAM-1 by nanocarriers (NCs) coated with anti-ICAM antibodies or peptides, such as the case of liposomes, nanoparticles, dendrimers, micelles, protein conjugates, and so on, induces a series of signal cascades and actin reorganization in ECs, leading to vesicular transport both into and across these cells. [15] [16] [17] [18] This is mediated via the cell adhesion molecule (CAM) pathway, a clathrin-and caveolae-independent route. 17, 18 The CAM pathway is effective across a broad spectrum of carrier sizes (from the nano-to the micro-scale), in contrast to clathrin-or caveolae-mediated pathways that associate with 100-150 nm and 50-70 nm vesicles, respectively. 18, 19 This correlates well with the fact that ICAM-1 contributes to mobilization of leukocytes, 20 a much larger "ligand" than the natural molecular counterparts transported via clathrin or caveolar means. The signal cascades that associate with endothelial uptake of anti-ICAM NCs involve protein kinase C, Src kinases, Rho, Ca 21 , sphingomyelinase-mediated generation of ceramide, and so on, which are reminiscent of those elicited on leukocyte binding to ECs during inflammation. 4, 17, 18 Similarly, the actin reorganization observed in both events are analogous and consist of mobilization of cortical into actin stress fibers. 4, 17, 18 Ultimately, endothelial targeting and vesicular transport via ICAM-1 has shown promise for diagnostic imaging and drug delivery applications in the context of cancer, pulmonary, cardiovascular, genetic, and other diseases. [8] [9] [10] [11] [12] [13] [14] However, due to the role of ICAM-1-mediated leukocyte adhesion and signaling in inflammation, [5] [6] [7] the secondary effects of engaging this receptor and/or blocking it from its natural counterparts are not known. In fact, this aspect has not been carefully examined yet for most of the targeted drug delivery systems described in the literature.
Given that cell-surface receptors and markers are typically involved in complex functions and/or signaling processes important to maintaining homeostasis, it is logical to assume that engagement by targeted drug carriers could lead to either beneficial or detrimental side effects, depending on their specific patho-physiological role. In the case of ICAM-1, it has been postulated that engagement by antibodies or drug carriers could lower the availability of this marker for engagement by its natural "ligands" (b 2 integrins, LFA-1 and Mac-1, present on the leukocyte surface), 5 therefore, attenuating inflammation, which may render secondary benefits. 21 Conversely, it is known that ICAM-1 binding by leukocytes initiates pro-inflammatory cascades, including release of cytokines, generation of reactive oxygen species, expression of other CAMs, alteration of endothelial permeability, and so on. 6, 7 ;
hence, ICAM-1 engagement by NCs could result in similar side effects.
In this context, an interesting biological process associated with ICAM-1 overexpression during inflammation and its engagement by leukocytes is that of endothelial release of the ectodomain of ICAM-1, which can then circulate as the "soluble" form of this molecule (sICAM-1). 6, 22 Release of sICAM-1 is believed to occur via cleavage of the ICAM-1 ectodomain by proteases, such as matrix metalloproteinase-9
(MMP-9). 23 Additional proteases (e.g., TNFa-converting enzyme
[TACE] and elastase) may also be directly involved in ICAM-1 cleavage, [24] [25] [26] or others may indirectly play a role in this process, such as in the case of matrix metalloproteinase-2 (MMP-2), which is involved in cleavage of pro-MMP-9 into the active form of this protease. 27, 28 The literature describes sICAM-1 as an inflammatory marker and regulator, which can promote the inflammatory response. 6, 22 Serum sICAM-1 appears to be low in healthy individuals, but its levels increase in many pathologies, associating with the disease progression and severity, as in the case of cancer, cardiovascular disease, immune syndromes and, generally, maladies involving chronic inflammation. 6, 22 This association is not merely circumstantial, but sICAM-1 appears functionally involved in these diseases. 22 For instance, sICAM-1 aids in tumor progression by promoting angiogenesis and shielding tumors from cytotoxic lymphocytes, and it promotes a pro-inflammatory phenotype by inducing the production of factors such as MIP-1a, IL-6, or TNFa. 22, [29] [30] [31] [32] Therefore, in this work we began studying aspects relative to the potential secondary effects of endothelial ICAM-1 targeting, focusing on the influence of anti-ICAM NCs on endothelial release of sICAM-1. The results we obtained will help rationally inform the future design of drug carriers and selection of potential applications using this strategy.
| MATERIALS A ND METHODS

| Antibodies and reagents
Monoclonal mouse anti-human ICAM-1 (clone R6. were from EMD Millipore (Billerica, MA). Unless specified, all other reagents were from Sigma-Aldrich (St. Louis, MO).
| Preparation and characterization of anti-ICAM NCs
Model polymer NCs were prepared by coating via surface adsorption with unlabeled or 125 I-labeled anti-ICAM or non-specific IgG onto 100 nm, green Fluoresbrite® polystyrene particles (anti-ICAM NCs vs.
IgG NCs), as described. 11 Briefly, 10 13 NCs/ml and 5 mM antibody were incubated for 1 hr, followed by washing and centrifugation to remove unbound antibody. Final resuspension was at 7 3 10 11 NCs/ ml in phosphate buffered saline containing 1% bovine serum albumin, followed by sonication. The diameter of coated NCs was measured using particle tracking (Nanosight LM10, Malvern Instruments; Westborough, MA), while the polydispersity index (PDI) and f-potential were obtained by dynamic light scattering and electrophoretic mobility, respectively (Zetasizer Nano-S90; Malvern Instruments; Westborough, MA mg/ml endothelial cell growth supplement, 100 mg/ml heparin, 100 U/ ml penicillin, and 100 mg/ml streptomycin. Cells were grown at 378C, 5% CO 2 , and 95% relative humidity on either 1% gelatin-coated coverslips or uncoated 1.0 mm-pore transwell inserts. Where indicated, cells
were stimulated for 16-20 h with 10 ng/ml tumor necrosis factor a (TNFa) to induce endothelial activation. Rochester, NY). Images were taken using an ORCA-ER camera (Hamamatsu; Bridgewater, NJ) and SlideBook 4.2 software (Intelligent Imaging Innovations; Denver, CO), and analyzed using Image-Pro 6.3 (Media Cybernetics, Inc.; Bethesda, MD). As in previous studies, the total number of NCs associated per cell (total green NC signal) and the number of NCs internalized within cells (total green signal minus green signal that colocalized with "surface" red signal) were quantified. This was achieved using an algorithm that normalizes the area of specific fluorescence (over a threshold background) to the number of pixels that correspond to the size of a single NC at the magnification used. I was determined using trichloroacetic acid precipitation and subtracted from these measurements, to eliminate any contribution of free tracer. 33 The absolute number of NCs in the cell fraction was calculated from the specific 125 I activity of the carrier preparation, as described. 16 
| Release of sICAM-1 by ECs
Quiescent versus TNFa-activated HUVECs, grown on coverslips or transwells, were incubated at 378C in the absence versus presence of anti-ICAM NCs or IgG NCs (7 3 10 10 NCs/ml). For transwell experiments, NCs were added to the apical chamber for 30 min (pulse), followed by washing to remove unbound NCs, and incubation for additional time in carrier-free medium up to a total of 1 or 5 h (chases). After each time, the cell medium was collected and centrifuged at 3,000g for 5 min, followed by 1 min centrifugation at 17,000g to remove residual NCs, cells, and debris. The supernatants were used to quantify sICAM-1 by ELISA according to the manufacturer's instructions, followed by colorimetric detection using a SpectraMax M2e microplate reader (Molecular Devices; Sunnyvale, CA) at 450 nm. Similar experiments were performed in the presence of 3 mM amiloride, which inhibits CAM-mediated transport, 17, 18 and 25 mM MMP-9 or MMP-2 inhibitors (MMP-9i; MMP2i), individually or in combination (Mixed MMPi).
| Validation of sICAM-1 differential shedding versus diffusion in transwell models
To verify lack of diffusion (indicative of differential release) of sICAM-1 across the EC monolayer, 2 ng/ml exogenous sICAM-1 was added to either the apical or basolateral chambers and incubated at 378C for 4. To validate the specificity of this differential pattern, we tested the passive permeability of the EC monolayer and the transwell filter (Figure 1c) . In the absence of cells, addition of exogenous sICAM-1 to the apical chamber resulted in a similar distribution in both compartments (56% apical and 64% basolateral; Figure 1c and Supporting Information Figure S1 ). This indicates that sICAM-1 can diffuse through the filter pores, as expected. Then, we added exogenous sICAM-1 to either the apical or basolateral chambers separated by ECs, and sICAM-1 was measured in either chamber after 4. Information Figure S2 ). Since cells alone release more sICAM-1 to the basolateral side, it was expected that adding exogenous sICAM-1 to this chamber would enhance sICAM-1 to a lesser extent than adding it to the apical side (Supporting Information Figure S2 ). Yet, when comparing the absolute amount of exogenous sICAM-1 recovered from the basolateral versus apical chambers (middle bars in Supporting Information Figure S1 ), it is clear that this corresponds to almost all sICAM-1 added. These results indicate that there is minimal (if any) passive leakage of sICAM-1 across EC monolayers and the levels of sICAM-1 detected in this model correspond to differential basolateral and apical release by ECs.
| MMP mechanism of sICAM-1 release by ECs
It has been reported that release of sICAM-1 by ECs may be in part contributed by shedding of ICAM-1 expressed at the cell-surface, a phenomenon also observed for other endothelial CAMs. 22, [29] [30] [31] [32] This is believed to be mediated via cleavage of the ICAM-1 ectodomain by proteases, such as the case for matrix metalloproteinase MMP-9. Interestingly, compared with respective controls in each chamber, the effect caused by MMP-9 was greater in the apical versus basolateral chamber (48% vs. 73% of respective chamber controls; Figure 2b ).
Comparing the absolute amount of sICAM-1 contributed by MMP-9 to either chamber (Figure 2c ), we observed that inhibition of this proteinase more readily decreased sICAM-1 in the apical versus basolateral chamber (78% vs. 35% contribution). MMP-2 inhibition also decreased apical sICAM-1 release (56% of control), although no effect was observed with regard to basolateral release (96% of control; Figure 2b ).
In fact, when comparing the absolute amount of sICAM-1 contributed by MMP-2 in these chambers, only apical activity was found (114% vs. 8% contribution; Figure 2c ). Despite observing MMP-9 and MMP-2 effects in the apical chamber, simultaneous inhibition of both proteinases did not render enhanced or additive effects on this side (37% of control, statistically similar to MMP-9 inhibition alone) and little inhibition arose in the basolateral chamber (92% of control; Figure 2b ). Altogether, these results suggest that both MMPs are functionally involved in sICAM-1 release to the apical space, with MMP-9 contributing to a greater extent, while MMP-9 alone contributes to basolateral sICAM-1 release and this contribution is lower than that at the apical side.
| Effect of anti-ICAM NCs on sICAM-1 release by ECs
In addition to pro-inflammatory factors alone, sICAM-1 release has been postulated to associate with other events. For instance, binding 
| DISCUSSION
Targeting of imaging agents and drug NCs to endothelial ICAM-1 holds promise in the context of diagnostic and therapeutic interventions focused at the vascular endothelium. [8] [9] [10] [11] [12] [13] [14] Binding of drug NCs to ICAM-1 on the endothelial surface induces signaling conducive to NC transport into and across this lining. [16] [17] [18] Although numerous cell culture and in vivo studies suggest that no acute toxicity associates with this strategy, [8] [9] [10] [11] [12] [13] [14] potential side effects must be carefully examined for further translational development. This work investigated the influence of ICAM-1 targeting on endothelial release of sICAM-1, a marker of inflammation that associates with a variety of maladies, 22 revealing an unexpected benefit of anti-ICAM NCs.
During inflammation, which underlies most pathologies, ICAM-1 becomes overexpressed on the surface of activated ECs and, concomitantly, sICAM-1 levels increase in serum. 22 TNFa and other proinflammatory factors (IL-1b, IL-6, IFN-g, angiotensin II, etc.) induce such an outcome. 22, 29, 41 The mechanism for sICAM-1 release is not fully characterized, yet the soluble form of this molecule can arise from proteolytic cleavage of the ectodomain of cell-surface ICAM-1. 23, 29, 41 We reproduced this by treating ECs with TNFa, using both a solid surface model and a transwell filter model. While the first model is commonly described, [24] [25] [26] 41 sICAM-1 release on polarized linings has been predominantly reported for epithelial cells, not ECs. 42, 43 From our study, it appears that activated ECs separating apical and basolateral compartments released slightly greater levels of sICAM-1 than those not polarized (Figure 1 ), where basolateral levels surpassed apical ones.
While we could not find direct comparisons on both models in the literature, work showing independent experiments using solid-surface and transwells seems to support our finding. 44 Also, preferential basolateral secretion is supported by previous studies. 45 The fact that, in vivo, sICAM-1 has been found not only in serum but it has also been implicated in angiogenesis, migration of vascular smooth muscle cells, and other events involving the basolateral space, 6 indicates that its differential distribution reflects a functional purpose. Hence, both apical and basolateral release events must be considered.
MMP-9 was involved in endothelial release of sICAM-1 on inflammatory stimulation (Figure 2 ), in agreement with the literature. 23 It has been shown that ICAM-1 provides cell-surface docking for pro-MMP-9, the latent form of MMP-9, 23 and then the active enzyme can cleave ICAM-1 at its membrane-proximal domain. 23 Yet, our results also suggest that the contribution of MMP-9 to this event was partial and there must be other factors involved. Inhibition of MMP-2 seemed to influence sICAM-1 release and this could be an additional mechanism. However, simultaneous inhibition of MMP-9 and MMP-2 did not render an enhanced effect, ruling out this option, in accord with the fact that ICAM-1 is not known to be an MMP-2 substrate. Yet, MMP-2 may indirectly play a role in this process since it can cleave pro-MMP-9 into MMP-9. 27, 28 This would explain why MMP-2 inhibition resulted in a reduction of sICAM-1 release similar to MMP-9 inhibition, but no additive effects were found when inhibiting both (Figure 2 ).
Hence, additional factors must contribute to sICAM-1 release in our assays. Other studies have shown mRNA transcripts specifically encoding sICAM-1, 46,47 but our assays involve pulse-chase experiments to examine release within 30 min, and de novo protein synthesis is unlikely to play a major role. Other molecules that may be involved in this process include TACE and elastase, as seen previously. [23] [24] [25] [26] While inhibiting MMPs was expected to decrease sICAM-1 release, the inhibitory effect of anti-ICAM NCs on this event (Figure 4) was unexpected, based on the fact that ICAM-1 binding by its natural ligands, leukocytes, elicits (instead of reduces) sICAM-1 release. This may help dynamic detachment of leukocyte-endothelial engagement in areas where the leukocyte "samples" the endothelial surface prior to extravasation. 4, 23, [34] [35] [36] [37] It may also play a role in loosening leukocyteendothelial attachment after extravasation and to subsequently downregulate cell-surface ICAM-1. 4, 23, [34] [35] [36] [37] Because the signaling cascades induced in ECs by NC binding to ICAM-1 are reminiscent of those induced by leukocytes, 4 an increase in sICAM-1 release was expected.
However, the reduction observed can be understood based on the fact that anti-ICAM NCs are rapidly internalized by ECs and, since they bind to ICAM-1, their internalization removes ICAM-1 from the plasmalemma, as we have previously shown. 40 In fact, we have observed that most cell-surface ICAM-1 is internalized during this event (as verified in Figure 6a ) and then, once within cells, NCs traffick to lysosomes or are transcytosed, whereas a fraction of internalized ICAM-1 recycles back to the plasmalemma after 1 h. 15, 16, 40 Hence, by reducing the availability of membrane ICAM-1 on the cell-surface, anti-ICAM NCs reduced sICAM-1 release. This was demonstrated by the fact that inhibiting NC uptake with amiloride counteracted the inhibitory effects on sICAM-1 release (Figure 6b ,c) and that only negligible amounts of sICAM-1 was fund in cell lysates. In previous publications, we have shown that amiloride decreased endocytosis of anti-ICAM NCs without affecting their binding 17, 18 ; hence, validating this mechanism. In addition, the time and location of this inhibitory effect (predominant on the apical side at 30 min; Figure 4 ) pairs well with a role for anti-ICAM NC endocytosis in lowering surface ICAM-1 and sICAM-1 release.
| C O NC LU S I O N S
Given that elevated sICAM-1 is considered a pathological marker implicated in the development of numerous pathologies (inflammation, atherosclerosis, cancers, neurological disorders, autoimmune diseases, etc.), 6, 22 attenuation of its release may benefit these conditions. Inter- which we aim to investigate in the future.
